Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
No report run on this ticker yet
Only preliminary foundational data below
Sign in to run a fresh report
Free · results in ~10 min
For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Neurocrine Biosciences Inc. (NBIX) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Neurocrine Biosciences Inc.
NBIX NASDAQ
Healthcare · Drug Manufacturers - Specialty & Generic
San Diego, CA 92130, United States
neurocrine.com
Price
$151.60
Market Cap
$15.9B
Employees
2,500
Beta
0.39
Avg Volume
1,261,480
CEO
Mr. Kyle W. Gano Ph.D.
Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company headquartered in San Diego, California. The company specializes in discovering, developing, and commercializing medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its marketed portfolio addresses a range of conditions, including tardive dyskinesia and chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, adrenal insufficiency, endometriosis, and uterine fibroids. Key products include INGREZZA for movement disorders, ALKINDI and Efmody for adrenal-related conditions, Orilissa and Oriahnn for gynecologic disorders, and CRENESSITY for congenital adrenal hyperplasia. Following the acquisition of Soleno Therapeutics, Neurocrine Biosciences also offers VYKAT XR, a therapy targeting hyperphagia in Prader-Willi syndrome, expanding its presence in rare endocrine and metabolic diseases. The company serves patients and healthcare providers in the United States and internationally, playing a significant role in specialty pharmaceuticals for complex central nervous system and endocrine conditions. Founded in 1992, it operates today as a key player in the biopharmaceutical segment of the healthcare market.
Runs with full report
Earnings Schedule
Checked daily · calendar updated Aug 13 No upcoming print on the calendar yet — companies typically confirm a few weeks ahead. Last print was Jul 30, 2026.
EPS surprise history — vs analyst consensus · 5 prints of vendor history
+94.6%
Feb '26
+16.7%
Feb '26
+2.3%
Mar '26
+14.1%
May '26
+45.4%
Jul '26
| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Jul 30, 2026 | $1.96 | $2.85 +45.4% | — | — |
| May 5, 2026 | $1.70 | $1.94 +14.1% | — | — |
| Mar 26, 2026 | $2.18 | $2.23 +2.3% | — | — |
| Feb 27, 2026 | $0.18 | $0.21 +16.7% | — | — |
| Feb 16, 2026 | $-10.85 | $-0.59 +94.6% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Aug 5, 2026 | 4 | View |
| Jul 31, 2026 | S-8 | View |
| Jul 31, 2026 | 8-K/A | View |
| Jul 31, 2026 | 10-Q | View |
| Jul 30, 2026 | 4 | View |
| Jul 30, 2026 | 8-K | View |
| Jul 27, 2026 | SCHEDULE 13G/A | View |
| Jul 13, 2026 | 4 | View |
| Jul 13, 2026 | 4 | View |
| Jul 10, 2026 | 144 | View |
| Jul 9, 2026 | 4 | View |
| Jul 9, 2026 | 144 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 13, 2026 3:13pm (just now)
Current data · timestamped when a report runs
$151.60
Change · Aug 13
-4.89 (-3.12%)
Day Range
$150.45 – $155.81
52-Week Range
$122.14 – $186.12
50-Day MA
$168.21
200-Day MA
$146.84
Volume
128,027.00
Share Structure
Outstanding
101,600,000.00
Float
97,558,818.00
Free Float
96.0%
High free float
— 96.0% of shares trade freely, ~4% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
TD Twelve Data statement
HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEXStock Price / EPS (Diluted)
32.46
Stock Price: $151.60
EPS (Diluted): 4.67
EPS (Diluted): 4.67
P/B Ratio (Price vs net asset value)
HEXStock Price / Book Value Per Share
4.78
Stock Price: $151.60
Total Equity: $3.25B
Shares: 102,500,000
Total Equity: $3.25B
Shares: 102,500,000
EV/EBITDA (Total value vs operating profit)
HEXEnterprise Value / EBITDA
22.63
Market Cap: $15.91B
Total Debt: $0.00
Cash: $713.00M
EBITDA: $645.10M
Total Debt: $0.00
Cash: $713.00M
EBITDA: $645.10M
Enterprise Value (Takeover price (cap + debt - cash))
HEXMarket Cap + Total Debt - Cash
$14.6B
Market Cap: $15.91B
Total Debt: $0.00
Cash: $713.00M
Total Debt: $0.00
Cash: $713.00M
Gross Margin (Revenue left after direct costs)
HEXGross Profit / Revenue
98.2%
Gross Profit: $2.81B
Revenue: $2.86B
Revenue: $2.86B
Operating Margin (Revenue left after all operations)
HEXOperating Income / Revenue
21.6%
Operating Income: $619.10M
Revenue: $2.86B
Revenue: $2.86B
Net Margin (Revenue left as actual profit)
HEXNet Income / Revenue
16.7%
Net Income: $478.60M
Revenue: $2.86B
Revenue: $2.86B
ROE (Profit from shareholder equity)
HEXNet Income / Total Equity
14.7%
Net Income: $478.60M
Total Equity: $3.25B
Total Equity: $3.25B
ROIC (Profit from all invested capital)
HEXNOPAT / Invested Capital
16.5%
Operating Income: $619.10M
Tax Rate: 32.2%
Equity: $3.25B
Total Debt: $0.00
Cash: $713.00M
Tax Rate: 32.2%
Equity: $3.25B
Total Debt: $0.00
Cash: $713.00M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
HEXCurrent Assets / Current Liabilities
3.39
Current Assets: $2.52B
Current Liabilities: $743.40M
Current Liabilities: $743.40M
Debt/Equity (Leverage — debt vs equity)
HEXTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $3.25B
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $3.25B
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
HEXRevenue / Shares Outstanding
$27.91
Revenue: $2.86B
Shares: 102,500,000
Shares: 102,500,000
Book Value/Share (Net assets per share)
HEX(Total Assets - Total Liabilities) / Shares
$31.74
Total Equity: $3.25B
Shares: 102,500,000
Shares: 102,500,000
FCF/Share (Real cash generated per share)
HEX(Operating Cash Flow + CapEx) / Shares
$7.30
Operating CF: $782.70M
CapEx: -$34.00M
Shares: 102,500,000
CapEx: -$34.00M
Shares: 102,500,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TDLast Annual Dividend / Stock Price
—
Last Dividend: $0.00
Stock Price: $151.60
Stock Price: $151.60
Payout Ratio (Earnings paid out as dividends)
HEXDividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $478.60M
Net Income: $478.60M
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Aug 13, 2026 3:13pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.5B | $1.9B | $2.4B | $2.9B |
| Cost of Revenue | $14.3M | $23.2M | $39.7M | $34.0M | $52.1M |
| Gross Profit | $1.1B | $1.5B | $1.8B | $2.3B | $2.8B |
| Operating Expenses | $1.0B | $1.2B | $1.6B | $1.8B | $2.2B |
| Operating Income | $102.5M | $249.0M | $250.9M | $570.5M | $619.1M |
| Net Income | $89.6M | $154.5M | $249.7M | $341.3M | $478.6M |
| EBITDA | $113.4M | $264.1M | $268.7M | $594.0M | $645.1M |
| EPS | $0.95 | $1.61 | $2.56 | $3.40 | $4.81 |
| EPS (Diluted) | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 |
Balance Sheet (Annual)
Last updated: Aug 13, 2026 3:13pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $340.8M | $262.9M | $251.1M | $233.0M | $713.0M |
| Total Current Assets | $972.8M | $1.5B | $1.6B | $1.7B | $2.5B |
| Total Assets | $2.1B | $2.4B | $3.3B | $3.7B | $4.6B |
| Current Liabilities | $245.8M | $537.7M | $654.8M | $507.7M | $743.4M |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $698.5M | $660.9M | $1.0B | $1.1B | $1.4B |
| Total Equity | $1.4B | $1.7B | $2.2B | $2.6B | $3.3B |
| Retained Earnings | -$635.8M | -$406.8M | -$157.1M | $29.2M | $447.7M |
Cash Flow (Annual)
Last updated: Aug 13, 2026 3:13pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $256.5M | $339.4M | $389.9M | $595.4M | $782.7M |
| Capital Expenditure | -$23.4M | -$16.5M | -$28.3M | -$38.2M | -$34.0M |
| Free Cash Flow | $233.1M | $322.9M | $361.6M | $557.2M | $748.7M |
| Acquisitions (net) | $0 | -$42.7M | $0 | $0 | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | $0 | $0 | -$300.0M | -$167.7M |
| Net Change in Cash | $153.7M | -$73.3M | -$11.6M | -$18.1M | $480.0M |
Growth Trends (YoY %)
Last updated: Aug 13, 2026 3:13pm (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +31.3% | +26.8% | +24.8% | +21.4% |
| Gross Profit Growth | +30.9% | +26.1% | +25.7% | +21.0% |
| Operating Income Growth | +142.9% | +0.8% | +127.4% | +8.5% |
| Net Income Growth | +72.4% | +61.6% | +36.7% | +40.2% |
| EBITDA Growth | +132.9% | +1.7% | +121.1% | +8.6% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Onyia Jude | G-Gift | 2,409.00 | $0.00 | $0 |
| 2026-07-29 | Norwalk Leslie V | M-OptionExercise | 842.00 | $0.00 | $0 |
| 2026-07-28 | Norwalk Leslie V | S-Sale | 1,250.00 | $182.01 | $227,508 |
| 2026-07-10 | Delaet Ingrid | M-OptionExercise | 4,367.00 | $0.00 | $0 |
| 2026-07-10 | Delaet Ingrid | S-Sale | 4,367.00 | $181.02 | $790,514 |
| 2026-07-09 | Delaet Ingrid | M-OptionExercise | 8,433.00 | $0.00 | $0 |
| 2026-07-09 | Delaet Ingrid | S-Sale | 8,433.00 | $178.72 | $1.5M |
| 2026-07-09 | Lippoldt Darin | M-OptionExercise | 10,000.00 | $0.00 | $0 |
| 2026-07-09 | Lippoldt Darin | S-Sale | 10,000.00 | $179.60 | $1.8M |
| 2026-07-08 | Delaet Ingrid | M-OptionExercise | 2,737.00 | $0.00 | $0 |
| 2026-07-08 | Delaet Ingrid | S-Sale | 2,737.00 | $178.54 | $488,672 |
| 2026-07-07 | Delaet Ingrid | M-OptionExercise | 3,401.00 | $0.00 | $0 |
| 2026-07-07 | Delaet Ingrid | S-Sale | 3,401.00 | $178.57 | $607,305 |
| 2026-06-29 | Lippoldt Darin | M-OptionExercise | 8,110.00 | $0.00 | $0 |
| 2026-06-29 | Lippoldt Darin | M-OptionExercise | 1,690.00 | $0.00 | $0 |
| 2026-06-29 | Lippoldt Darin | S-Sale | 8,110.00 | $170.03 | $1.4M |
| 2026-06-29 | Lippoldt Darin | S-Sale | 1,690.00 | $170.81 | $288,676 |
| 2026-06-26 | Lippoldt Darin | M-OptionExercise | 200.00 | $0.00 | $0 |
| 2026-06-26 | Lippoldt Darin | S-Sale | 200.00 | $169.57 | $33,913 |
| 2026-06-05 | SHERWIN STEPHEN A | M-OptionExercise | 15,000.00 | $0.00 | $0 |
Industry Benchmarks
Compares NBIX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for NBIX — it's generated by the pipeline (
market-narrative step).
Claude Reading
No AI findings yet for NBIX — they're generated by the
pipeline (
ai-findings step) when a report is run on this ticker.
GPT Reading
No GPT reading yet for NBIX — it's generated by the
pipeline (
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
No Grok reading yet for NBIX — it's generated by the
pipeline (
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · four lenses
No community reviews yet for NBIX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.530 · 761561a2 · 2026-08-12 19:06:35